Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
11 juil. 2022 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV IMC-M113V, T cell receptor bispecific, targets an HIV Gag antigen Single Ascending Dose portion of Phase...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™
25 juin 2022 04h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
22 juin 2022 20h01 HE
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins
15 juin 2022 08h30 HE
|
SciSparc Ltd
JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty,...
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
03 juin 2022 07h00 HE
|
HOOKIPA Pharma Inc.
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector...
Monoclonal Antibodies Market Trends 2022 | North America, Europe, & APAC Industry Forecasts 2028: Graphical Research
12 mai 2022 05h00 HE
|
Graphical Research
Pune, India, May 12, 2022 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size is predicted to witness remarkable growth during the forecast period, due to the rising incidence of...
Persbericht Biocartis Group NV: Biocartis kondigt presentatie van drie Idylla™ studies aan op 32ste Europees Congres voor Klinische Microbiologie & Infectieziekten (ECCMID)
25 avr. 2022 01h00 HE
|
Biocartis NV
PERSBERICHT: 25 april 2022, 07:00 CEST Biocartis kondigt presentatie van drie Idylla™ studies aan op 32ste Europees Congres voor Klinische Microbiologie & Infectieziekten (ECCMID) Mechelen,...
Press release Biocartis Group NV: Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
25 avr. 2022 01h00 HE
|
Biocartis NV
PRESS RELEASE: 25 April 2022, 07:00 CEST Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Mechelen,...
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
25 mars 2022 08h00 HE
|
Icosavax, Inc.
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology;...
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
02 mars 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual...